Main menu

Recent Pfizer Press Releases

2/3/14 7:00am EST
Pfizer Announces Positive Top-Line Results From PALOMA-1 Evaluating Palbociclib Plus Letrozole in Women with Advanced Breast Cancer

Clinical Benefit Demonstrated For Potential First-in-Class CDK 4 and 6 Inhibitor

Pfizer Inc. (NYSE: PFE) today announced that the randomized Phase 2 trial [PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer.  

more...
1/28/14 7:00am EST
Pfizer Reports Fourth-Quarter and Full-Year 2013 Results; Provides 2014 Financial Guidance

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2013. As a result of the full disposition of Zoetis(3) on June 24, 2013, the financial results of the Animal Health business are reported as a discontinued operation in the consolidated statements of income for full-year 2013, and fourth-quarter and full-year 2012. Results and guidance are summarized below.

more...
1/27/14 7:00am EST
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer

An Ongoing, Third Phase 3 Trial is Evaluating Dacomitinib in First-Line in EGFR-Mutant NSCLC   

Pfizer Inc. (NYSE:PFE) today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer (NSCLC).

more...
1/23/14 8:00am EST
Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study

Pfizer Inc. (NYSE: PFE) announced today top-line results from a Phase 3 study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic low back pain.  In this study, ALO-02 met the primary efficacy endpoint, demonstrating a statistically significant difference from placebo.

more...
1/22/14 10:00am EST
New Survey Reveals What Match.Com Members Think About Smoking Cigarettes And Dating

Match.com and Pfizer (NYSE: PFE) today announced results from a recent survey showing that single smokers may want to consider breaking up with their cigarettes as they look for that special someone this year.  Nearly 9 out of 10 (89 percent) respondents said they prefer not to date someone who smokes, and when asked which actions were unacceptable on a first date, more said taking a smoke break (51 percent) than checking one’s phone (45 percent) or being late (40 percent). 

Match.com and Pfizer (NYSE: PFE) today announced results from a recent survey showing that single smokers may want to consider breaking up with their cigarettes as they look for that special someone this year.  Nearly 9 out of 10 (89 percent) respondents said they prefer not to date someone who smokes, and when asked which actions were unacceptable on a first date, more said taking a smoke break (51 percent) than checking one’s phone (45 percent) or being late (40 percent). 
 
more...
1/17/14 10:15am EST
Statement from Pfizer Chief Medical Officer on the 50th Anniversary of the First Surgeon General's Report on Smoking and Health

Freda Lewis-Hall, M.D., Pfizer’s executive vice president and chief medical officer, today issued a statement regarding the 50th Anniversary of the First Surgeon General's Report on Smoking and Health.

more...

Pages